increased for medications that are commercially available in different concentrations. Liquid medications prescribed for pediatric patients require additional computation for weight-based dosing and conversion, increasing the possibility of miscalculation. Our survey confirmed that both dispensing and dose calculation errors have occurred when prescribing generic propranolol for infants with IH. Dose calculation errors occurred less often with propranolol 4.28 mg/mL, and a single formulation distributed from 1 specialty pharmacy precludes dispensing errors. Pediatric dermatologists, who typically encounter and treat IH more frequently than other specialists, did not report fewer errors than other prescribers.
Although our study was not designed to evaluate the frequency of medication errors, it should help raise awareness of the risks and hopefully prevent associated adverse events. If the generic formulation of propranolol is prescribed, it is important to educate caregivers to check that the label is marked with the appropriate concentration. It may be helpful to incorporate electronic medical record orders or use an assistant to verify the calculation. (Table I) . ACD-specific QoL questionnaires are limited, and include the Fragrance Quality of Life Index and the Contact DermatitiseSpecific Questionnaire. 1, 2 An important gap in the current literature on QoL in ACD is the assessment of QoL over time, specifically before and after patch testing.
Anastasia
Our goal was to review previous studies assessing the impact of patch testing on QoL in patients recruited from patch test clinics. We conducted a search in the PubMed database, using the key words ''quality of life'' and ''contact dermatitis'' or ''patch testing.'' Only those studies that prospectively evaluated patient-reported QoL at baseline (before patch testing) and at follow-up (after patch testing) were included. Follow-up time varied from 6 weeks to 6 months (Table  II) . Studies assessing occupational contact dermatitis were excluded.
In all studies, patch testing led to improved QoL outcomes (Table II) . [3] [4] [5] In the study by Thomson et al, the DLQI score showed significant improvement 2 months after patch testing, but no significant changes were observed in the 36-item Short Form Health Survey, suggesting that skin-specific QoL instruments may be able to better capture the effects of skin disease on QoL. 4 Unlike Thomson et al, who observed improvement only in patients with positive patch tests, Woo et al observed an improvement in DLQI scores in all patch-tested patients 6 weeks after testing, suggesting that all patients may benefit from general advice about skin management and barrier protection. 4, 5 Alternatively, patients with negative testing may benefit from resuming the use of products that they previously avoided because of concerns about contact allergies.
No studies to date have used ACD-specific QoL tools to prospectively assess the effect of patch testing on QoL. The studies reviewed suggest that the existing skin-specific QoL instruments may not adequately capture the impact of patch testing on QoL in ACD patients. The only existing ACD-specific QoL tools include the Fragrance Quality of Life Index, which is restricted to patients allergic to fragrance(s), and the Contact DermatitiseSpecific Questionnaire developed by Ayala et al. However, the latter has only been used in 1 study in a population of Italian patients with ACD. Several questions were adapted from the DLQI and Skindex-16, and 6 items about feelings and limitation of daily activities were added. Otherwise, no additional information is available about its development, reliability, and validation process.
In conclusion, these findings suggest that patch testing leads to improved QoL in patients with ACD. However, existing ACD-specific QoL instruments are limited, highlighting the need for a comprehensive, validated, and disease-specific QoL instrument in ACD. This tool would enable clinicians to better characterize the positive impact of allergen identification and education on their patients' QoL. Low risk of hemorrhagic complications after obtaining diagnostic skin biopsy specimens in a cohort of thrombocytopenic inpatients
To the Editor: Previous studies evaluating inpatient diagnostic skin biopsies have determined minimal risk for hematomas in noncoagulopathic patients. 1 However, the risk of bleeding after skin biopsies in thrombocytopenic patients or those with other bleeding risk factors remains unknown. In this study, we evaluated hemorrhagic complications after skin biopsy in high-risk patients. We searched the Research Patient Data Registry, a database containing records of patients from Brigham and Women's Hospital and Massachusetts General Hospital to identify inpatients who had skin biopsies between 2000 and 2015. Of 2878 patients, 300 were randomly selected with platelets #150,000/L, with 50% having platelets #20,000/ L and 50% having platelets between 20,000/L and 150,000/L. Patients without documentation of procedure details (n ¼ 91), without thrombocytopenia (n ¼ 1), or without a bedside skin biopsy (n ¼ 3) were excluded. Bleeding complications were defined as any bleeding during the hospitalization that required clinical intervention. The rate of bleeding complications was compared to published data on bleeding risks in nonthrombocytopenic patients (0%) after diagnostic skin biopsy. 1 We hypothesized a similarly low incidence among thrombocytopenic patients. As such, sample size was determined to achieve 80% power to detect equivalence to a rate of 1% bleeding complications with a range of 0% to 5%.
A total of 205 patients met the inclusion criteria (Table I) . One bleeding complication was identified in a patient with a 4-mm punch biopsy obtained from the calf by the primary (nondermatology) team that was left to heal by secondary intention. The patient had oozing at the biopsy site on the day of the biopsy procedure, which was stopped with pressure dressing. The total estimated blood loss was \25 mL. The patient had acute myeloid leukemia and a platelet count of 62,000/L. She was not taking any anticoagulants and lacked other risk factors for bleeding.
There were no other bleeding complications (Table II) . The bleeding complication rate of 1 out of 205 (0.49%) was not statistically different from the bleeding complication rate of 0% in nonthrombocytopenic patients (P ¼ .48). 1 We conclude that there is a low bleeding complication rate (0.49%) for diagnostic skin biopsies performed on inpatients with thrombocytopenia. The single bleeding complication was minor and occurred in a patient whose biopsy site was not sutured. This rate is statistically similar to the published data on bleeding risk after inpatient diagnostic skin biopsies in nonthrombocytopenic patients. 1 Bleeding risks were minimal in thrombocytopenic patients who were anticoagulated or had recent bleeding. Although 24 (11.7%) of patients received platelet transfusions on the day of the biopsy, 23 were transfused per protocol (not as prophylaxis) and had low platelets at the time of biopsy, suggesting that the impact of transfusion on overall bleeding risk was low.
Guidelines for skin biopsies in thrombocytopenic patients are limited and varied. 2, 3 Our data suggest that bleeding risks in patients whose platelet levels are \20,000/L are low, because none of the 75 patients with platelets #20,000/L had bleeding complications. This finding should diminish physician discomfort regarding skin biopsies in thrombocytopenic patients and reduce individual and institutional variability regarding platelet thresholds required to perform skin biopsies. 
